The study, sponsored by the University of Aarhus, aimed to investigate the metabolic changes induced by OSA and the effects of massive weight loss post-bariatric surgery on inflammation and insulin sensitivity. Given the high prevalence of OSA among obese individuals and its association with significant comorbidities, the findings could have substantial implications for the development of therapeutic strategies targeting inflammation and metabolic disorders. The market for obesity-related treatments, including bariatric surgery and associated metabolic therapies, is considerable, with ongoing demand for effective interventions. The discontinuation of the resveratrol and CPAP components may limit the study's broader applicability but allows for a focused analysis of weight loss effects, which is a critical area of interest in obesity management.